Hyqvia 400 Unit

HYQVIA 400 Unit is a subcutaneous solution containing hyaluronidase (human recombinant). It is used to facilitate the absorption of fluids and drugs administered subcutaneously. This product is manufactured by Takeda Canada Inc.

HYQVIA 400 Unit is primarily used to enhance the dispersion and absorption of other drugs or fluids when administered subcutaneously. Hyaluronidase (human recombinant) works by breaking down hyaluronic acid in the skin, which can help improve the distribution of injected substances. This can be particularly useful in situations where rapid absorption is desired, such as in the administration of fluids or medications that are typically given intravenously but can be administered subcutaneously with the aid of hyaluronidase.

Common effects of HYQVIA 400 Unit may include localized reactions at the injection site, such as redness, swelling, or itching. Some individuals might experience mild discomfort or pain during or after administration. These effects are generally temporary and resolve on their own. Severe or persistent reactions should be reported to a healthcare provider.

HYQVIA 400 Unit should be handled with care to avoid contamination. It is important to follow proper injection techniques and hygiene practices to minimize the risk of infection. Individuals with known allergies to hyaluronidase or any of the components in the solution should avoid using this product. Always consult with a healthcare provider before starting any new treatment.

HYQVIA 400 Unit may interact with other medications or substances, particularly those that are administered subcutaneously. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol or other substances that affect the skin or subcutaneous tissues may influence the effectiveness or safety of HYQVIA 400 Unit.